Shanghai - Delayed Quote CNY

Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SS)

14.30
-0.05
(-0.35%)
At close: 3:00:03 PM GMT+8
Loading Chart for 600521.SS
  • Previous Close 14.35
  • Open 14.30
  • Bid 14.29 x --
  • Ask 14.30 x --
  • Day's Range 14.17 - 14.37
  • 52 Week Range 13.49 - 21.55
  • Volume 14,298,331
  • Avg. Volume 19,426,022
  • Market Cap (intraday) 21.563B
  • Beta (5Y Monthly) 0.52
  • PE Ratio (TTM) 18.10
  • EPS (TTM) 0.79
  • Earnings Date --
  • Forward Dividend & Yield 0.20 (1.39%)
  • Ex-Dividend Date Jul 10, 2024
  • 1y Target Est --

Zhejiang Huahai Pharmaceutical Co., Ltd. operates as a pharmaceutical company in China and internationally. The company offers central neurological, cardiovascular, anti-viral, and other products, as well as APIs and intermediates. It also provides packaging components, such as high-density polyethylene bottles and polypropylene caps for pharmaceuticals. In addition, the company offers contract manufacturing and other services, as well as import and export trade services. The company was founded in 1989 and is headquartered in Linhai, China.

www.huahaipharm.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 600521.SS

View More

Performance Overview: 600521.SS

Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

600521.SS
19.98%
SSE Composite Index (000001.SS)
1.56%

1-Year Return

600521.SS
17.11%
SSE Composite Index (000001.SS)
8.21%

3-Year Return

600521.SS
22.51%
SSE Composite Index (000001.SS)
10.36%

5-Year Return

600521.SS
38.89%
SSE Composite Index (000001.SS)
18.59%

Compare To: 600521.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 600521.SS

View More

Valuation Measures

Annual
As of 5/13/2025
  • Market Cap

    21.64B

  • Enterprise Value

    27.00B

  • Trailing P/E

    18.16

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.21

  • Price/Book (mrq)

    2.21

  • Enterprise Value/Revenue

    2.87

  • Enterprise Value/EBITDA

    16.06

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    12.16%

  • Return on Assets (ttm)

    4.76%

  • Return on Equity (ttm)

    12.28%

  • Revenue (ttm)

    9.42B

  • Net Income Avi to Common (ttm)

    1.15B

  • Diluted EPS (ttm)

    0.79

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.35B

  • Total Debt/Equity (mrq)

    77.94%

  • Levered Free Cash Flow (ttm)

    -755.89M

Research Analysis: 600521.SS

View More

Company Insights: 600521.SS

Research Reports: 600521.SS

View More

People Also Watch